FMWA
TEVA icon

Forvis Mazars Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Forvis Mazars Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,131
Closed -$354K – 248
2017
Q3 		$354K Sell
20,131
-15,109
-43% -$340K 0.04% 168
2017
Q2 		$1.17M Sell
35,240
-2,075
-6% -$64.2K 0.13% 86
2017
Q1 		$1.2M Buy
37,315
+21,757
+140% +$742K 0.15% 76
2016
Q4 		$564K Sell
15,558
-9,440
-38% -$377K 0.07% 109
2016
Q3 		$1.15M Buy
24,998
+2,580
+12% +$135K 0.16% 73
2016
Q2 		$1.13M Buy
22,418
+1,678
+8% +$89.3K 0.17% 74
2016
Q1 		$1.11M Buy
20,740
+4,508
+28% +$265K 0.18% 69
2015
Q4 		$1.06M Buy
16,232
+3,160
+24% +$195K 0.16% 68
2015
Q3 		$738K Sell
13,072
-2,394
-15% -$155K 0.13% 79
2015
Q2 		$914K Sell
15,466
-406
-3% -$25K 0.14% 79
2015
Q1 		$989K Sell
15,872
-519
-3% -$30.2K 0.14% 80
2014
Q4 		$943K Buy
16,391
+551
+3% +$30.7K 0.15% 74
2014
Q3 		$851K Buy
15,840
+622
+4% +$33K 0.15% 76
2014
Q2 		$798K Sell
15,218
-1,381
-8% -$70.6K 0.14% 77
2014
Q1 		$878K Sell
16,599
-875
-5% -$40.4K 0.16% 83
2013
Q4 		$700K Sell
17,474
-3,181
-15% -$125K 0.13% 88
2013
Q3 		$780K Buy
20,655
+2,030
+11% +$79.2K 0.16% 84
2013
Q2 		$730K Buy
+18,625
New +$725K 0.58% 50

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Forvis Mazars Wealth Advisors's TEVA Position: Q4 2017 in Review

Forvis Mazars Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 20,131 shares — an estimated $354K sold.

Forvis Mazars Wealth Advisors first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $1.2M in Q1 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Forvis Mazars Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Forvis Mazars Wealth Advisors sold 20,131 Teva Pharmaceuticals shares in Q4 2017, an estimated $354K.
  • Forvis Mazars Wealth Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Forvis Mazars Wealth Advisors's Teva Pharmaceuticals position peaked at $1.2M in Q1 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q4 2017, filed 18 Jan 2018.